Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US10500215B2 · kind B2 · utility
0Cited by
26References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2018 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Oct 17, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.